Keros Therapeutics Net Income
| KROS Stock | USD 17.04 0.11 0.64% |
As of the 12th of February 2026, Keros Therapeutics secures the Risk Adjusted Performance of 0.0396, downside deviation of 2.52, and Mean Deviation of 2.2. Keros Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Keros Therapeutics variance and potential upside to decide if Keros Therapeutics is priced some-what accurately, providing market reflects its recent price of 17.04 per share. Given that Keros Therapeutics has jensen alpha of 0.0483, we recommend you to check Keros Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.
Keros Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.5 K | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -168.6 M | -160.2 M | |
| Net Loss | -94.2 M | -89.5 M | |
| Net Loss | -168.6 M | -160.2 M | |
| Net Loss | (5.76) | (6.04) | |
| Net Income Per E B T | 1.15 | 1.16 |
Keros | Net Income | Build AI portfolio with Keros Stock |
The evolution of Net Income for Keros Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Keros Therapeutics compares to historical norms and industry peers.
Latest Keros Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Keros Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Keros Therapeutics financial statement analysis. It represents the amount of money remaining after all of Keros Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Keros Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Keros Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (187.35 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Keros Net Income Regression Statistics
| Arithmetic Mean | (53,076,030) | |
| Coefficient Of Variation | (134.34) | |
| Mean Deviation | 60,484,274 | |
| Median | (1,335,000) | |
| Standard Deviation | 71,302,140 | |
| Sample Variance | 5084T | |
| Range | 186M | |
| R-Value | (0.87) | |
| Mean Square Error | 1336.6T | |
| R-Squared | 0.75 | |
| Slope | (12,256,986) | |
| Total Sum of Squares | 81343.9T |
Keros Net Income History
Other Fundumenentals of Keros Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Keros Therapeutics Net Income component correlations
Keros Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Keros Therapeutics is extremely important. It helps to project a fair market value of Keros Stock properly, considering its historical fundamentals such as Net Income. Since Keros Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Keros Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Keros Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Keros introduce new products? Factors like these will boost the valuation of Keros Therapeutics. Expected growth trajectory for Keros significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Keros Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.56 | Revenue Per Share | Quarterly Revenue Growth 35.758 | Return On Assets | Return On Equity |
Investors evaluate Keros Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Keros Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Keros Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Keros Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Keros Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Keros Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Keros Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Keros Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Keros Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Keros Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Keros Therapeutics or generate 0.0% return on investment in Keros Therapeutics over 90 days. Keros Therapeutics is related to or competes with Regenxbio, Verastem, Absci Corp, Niagen Bioscience, CytomX Therapeutics, Ventyx Biosciences, and MoonLake Immunotherapeuti. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commerc... More
Keros Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Keros Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Keros Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.52 | |||
| Information Ratio | 0.0073 | |||
| Maximum Drawdown | 20.93 | |||
| Value At Risk | (3.36) | |||
| Potential Upside | 5.33 |
Keros Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Keros Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Keros Therapeutics' standard deviation. In reality, there are many statistical measures that can use Keros Therapeutics historical prices to predict the future Keros Therapeutics' volatility.| Risk Adjusted Performance | 0.0396 | |||
| Jensen Alpha | 0.0483 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0091 | |||
| Treynor Ratio | 0.1597 |
Keros Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0396 | |||
| Market Risk Adjusted Performance | 0.1697 | |||
| Mean Deviation | 2.2 | |||
| Semi Deviation | 2.42 | |||
| Downside Deviation | 2.52 | |||
| Coefficient Of Variation | 2463.61 | |||
| Standard Deviation | 3.11 | |||
| Variance | 9.67 | |||
| Information Ratio | 0.0073 | |||
| Jensen Alpha | 0.0483 | |||
| Total Risk Alpha | (0.25) | |||
| Sortino Ratio | 0.0091 | |||
| Treynor Ratio | 0.1597 | |||
| Maximum Drawdown | 20.93 | |||
| Value At Risk | (3.36) | |||
| Potential Upside | 5.33 | |||
| Downside Variance | 6.34 | |||
| Semi Variance | 5.87 | |||
| Expected Short fall | (2.63) | |||
| Skewness | 0.9217 | |||
| Kurtosis | 3.29 |
Keros Therapeutics Backtested Returns
Currently, Keros Therapeutics is not too volatile. Keros Therapeutics has Sharpe Ratio of close to zero, which conveys that the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Keros Therapeutics, which you can use to evaluate the volatility of the firm. Please verify Keros Therapeutics' Downside Deviation of 2.52, mean deviation of 2.2, and Risk Adjusted Performance of 0.0396 to check out if the risk estimate we provide is consistent with the expected return of 0.0269%. The company secures a Beta (Market Risk) of 0.73, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Keros Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Keros Therapeutics is expected to be smaller as well. Keros Therapeutics right now secures a risk of 3.16%. Please verify Keros Therapeutics potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Keros Therapeutics will be following its current price movements.
Auto-correlation | -0.46 |
Modest reverse predictability
Keros Therapeutics has modest reverse predictability. Overlapping area represents the amount of predictability between Keros Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Keros Therapeutics price movement. The serial correlation of -0.46 indicates that about 46.0% of current Keros Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.46 | |
| Spearman Rank Test | -0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.77 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Keros Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Keros Therapeutics reported net income of (187.35 Million). This is 154.9% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 132.81% higher than that of the company.
Keros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics of similar companies.Keros Therapeutics is currently under evaluation in net income category among its peers.
Keros Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.1B | 1.4B | 1.2B | 1.2B | 1.1B | 693.2M | |
| Enterprise Value | 828.8M | 1.1B | 946.3M | 854.1M | 768.7M | 545.9M |
Keros Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Keros Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Keros Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Keros Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Keros Therapeutics' value.| Shares | Goldman Sachs Group Inc | 2025-06-30 | 883.6 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 878.7 K | Alkeon Capital Management, Llc | 2025-06-30 | 850.5 K | Geode Capital Management, Llc | 2025-06-30 | 829.3 K | Federated Hermes Inc | 2025-06-30 | 654 K | Redmile Group, Llc | 2025-06-30 | 552.5 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 524.3 K | Hhg Plc | 2025-06-30 | 472.4 K | Pdt Partners, Llc | 2025-06-30 | 332.8 K | Adar1 Capital Management Llc | 2025-06-30 | 5.4 M | Blackrock Inc | 2025-06-30 | 2.7 M |
Keros Fundamentals
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.044 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | (141.97 M) | ||||
| Shares Outstanding | 30.47 M | ||||
| Shares Owned By Insiders | 3.63 % | ||||
| Shares Owned By Institutions | 97.08 % | ||||
| Number Of Shares Shorted | 2.28 M | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 2.12 X | ||||
| Revenue | 3.55 M | ||||
| Gross Profit | 91.76 M | ||||
| EBITDA | (185.82 M) | ||||
| Net Income | (187.35 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 18.86 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 17.32 X | ||||
| Cash Flow From Operations | (160.87 M) | ||||
| Short Ratio | 6.60 X | ||||
| Earnings Per Share | 1.56 X | ||||
| Target Price | 22.88 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 522.49 M | ||||
| Total Asset | 615.89 M | ||||
| Retained Earnings | (568.78 M) | ||||
| Working Capital | 561.44 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
| Net Asset | 615.89 M |
About Keros Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.